Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 23;10:397. doi: 10.1038/s41467-019-08301-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Validation of additional drivers in WB1P mice using germline and somatic engineering. a Overview of the germline and somatic mouse models for mammary gland-specific Myc overexpression in mice with conditional Brca1 and Trp53 alleles. b Kaplan–Meier curves showing mammary tumor-specific survival for the different genotypes. WapCre;Brca1^F/F;Trp53^F/F;Col1a1^{invCAG-Myc-IRES-Luc/+} (WB1P-Myc) females showed a reduced mammary tumor-specific survival compared to WB1P littermates (97 days vs. 198 days; ****P < 0.0001 by Mantel-Cox test). c Kaplan–Meier curves showing mammary tumor-specific survival for the different non-germline models. Brca1^F/F;Trp53^F/F;Col1a1^{invCAG-Myc-IRES-Luc/+} (B1P-Myc) females injected with Lenti-Cre, B1P females injected with Lenti-MycP2ACre and WB1P females injected with Lenti-Myc showed a reduced mammary tumor-specific survival compared to B1P female mice injected with Lenti-Cre (respectively 126, 92, and 61 days after injection vs. 238 days after injection; ****P < 0.0001 by Mantel-Cox test). d Representative hematoxylin and eosin (HE) staining and immunohistochemical detection of E-cadherin, vimentin, ER and PR in tumors from WB1P-Myc females and in tumors from Lenti-Cre injected B1P-Myc mice, Lenti-MycP2ACre injected B1P mice and Lenti-Myc injected WB1P mice. Bar, 400 µm. e Overview of the intraductal injections performed in WapCre;Brca1^F/F;Trp53^F/F;Col1a1^{invCAG-Cas9-IRES-Luc/+} (WB1P-Cas9) females with high-titer lentiviruses encoding Myc and either a non-targeting (NT) sgRNA (Lenti-sgNT-Myc), a sgRNA targeting exon 2 of Rb1 (Lenti-sgRb1-Myc) or a sgRNA targeting exon 7 of Pten. f Kaplan–Meier curves showing mammary tumor-specific survival for the different models. WB1P-Cas9 females injected with Lenti-sgPten-Myc and Lenti-sgRb1-Myc showed a reduced mammary tumor-specific survival compared to WB1P-Cas9 female mice injected with Lenti-sgNT-Myc (respectively 30 and 52 days after injection vs. 70 days after injection, ****P < 0.0001 and ***P < 0.001 by Mantel-Cox test). g Boxplots depicting the fraction of modified Rb1 and Pten alleles in tumors from WB1P-Cas9 mice injected with Lenti-sgNT-Myc, Lenti-sgRb1-Myc and Lenti-sgPten-Myc. Boxes extend from the third (Q3) to the first (Q1) quartile (interquartile range, IQR), with the line at the median; whiskers extend to Q3 + 1.5 × IQR and to Q1 − 1.5 × IQR